Ataluren Fails to Pass Muster as Treatment for Severe Form of Cystic Fibrosis
PTC Therapeutics’ ataluren has failed to significantly improve respiratory function in nonsense mutation cystic fibrosis (nmCF), a severe form of the disease, according to results of a Phase 3 clinical trial. “We are disappointed with the outcome of this trial as there are no treatments that target the underlying cause…
